Patents by Inventor Kang Le

Kang Le has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Fluorinated polyimides with fluorene cardo structure as optical materials that have low absolute thermo-optic coefficients
    Patent number: 8668992
    Abstract: The present invention provides new polyimide materials suitable for use in optically transparent fiber composites, ribbon composites, and optical communications applications. The polyimide compounds include monomeric repeat units comprising a fluorinated moiety and a fluorene cardo structure. The polyimides exhibit good optical transparency and have a low absolute thermo-optic coefficient (|dn/dT|).
    Type: Grant
    Filed: June 1, 2011
    Date of Patent: March 11, 2014
    Assignee: Brewer Science Inc.
    Inventors: Wenbin Hong, Tantiboro Ouattara, Kang Le Wang
  • FLUORINATED POLYIMIDES WITH FLUORENE CARDO STRUCTURE AS OPTICAL MATERIALS THAT HAVE LOW ABSOLUTE THERMO-OPTIC COEFFICIENTS
    Publication number: 20120308835
    Abstract: The present invention provides new polyimide materials suitable for use in optically transparent fiber composites, ribbon composites, and optical communications applications. The polyimide compounds include monomeric repeat units comprising a fluorinated moiety and a fluorene cardo structure. The polyimides exhibit good optical transparency and have a low absolute thermo-optic coefficient (|dn/dT|).
    Type: Application
    Filed: June 1, 2011
    Publication date: December 6, 2012
    Applicant: BREWER SCIENCE INC.
    Inventors: Wenbin Hong, Tantiboro Ouattara, Heping Wang, Kang Le Wang
  • METHODS OF PRODUCING STRUCTURES USING A DEVELOPER-SOLUBLE LAYER WITH MULTILAYER TECHNOLOGY
    Publication number: 20120034419
    Abstract: Methods of forming microelectronic structures using multilayer processes are disclosed. The methods comprise the use of a developer-soluble protective layer adjacent the substrate surface in a multilayer stack to protect the substrate during pattern transfer. After etching, the pattern is transferred into the developer-soluble protective layer using a developer instead of etching required by previous methods. Conventional developer-soluble anti-reflective coatings and gap-fill materials can be used to form the protective layer. Custom layers with developer solubility can also be prepared. Microelectronic structures formed by the above processes are also disclosed.
    Type: Application
    Filed: August 4, 2011
    Publication date: February 9, 2012
    Applicant: BREWER SCIENCE INC.
    Inventors: Carlton Ashley Washburn, James E. Lamb, III, Brian A. Smith, Justin Lee Furse, Heping Wang, Kang Le Wang
  • Thiazolyl-benzimidazoles
    Patent number: 8044213
    Abstract: The invention is directed to compounds of formula (1) and pharmaceutically acceptable salts thereof, methods for the preparation thereof, and methods of use thereof.
    Type: Grant
    Filed: December 10, 2009
    Date of Patent: October 25, 2011
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Jianping Cai, Shaoqing Chen, Yi Chen, Xin-Jie Chu, Robert Alan Goodnow, Jr., Kang Le, Kin-Chun Luk, Steven Gregory Mischke, Peter Michael Wovkulich
  • Thiazolyl-Benzimidazoles
    Publication number: 20100160308
    Abstract: The invention is directed to compounds of formula (1) and pharmaceutically acceptable salts thereof, methods for the preparation thereof, and methods of use thereof.
    Type: Application
    Filed: December 10, 2009
    Publication date: June 24, 2010
    Inventors: Jianping Cai, Shaoqing Chen, Yi Chen, Xin-Jie Chu, Robert Alan Goodnow, JR., Kang Le, Kin-Chun Luk, Steven Gregory Mischke, Peter Michael Wovkulich
  • Thiazoles as inhibitors of 11?-hydroxysteroid dehydrogenase
    Patent number: 7645773
    Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, type II diabetes mellitus and metabolic syndrome.
    Type: Grant
    Filed: January 8, 2007
    Date of Patent: January 12, 2010
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Paul Gillespie, Robert Alan Goodnow, Jr., Agnieszka Kowalczyk, Kang Le, Qiang Zhang
  • Thiazolyl-benzimidazoles
    Patent number: 7504513
    Abstract: The invention is directed to compounds of formula (1) and pharmaceutically acceptable salts thereof, methods for the preparation thereof, and methods of use thereof.
    Type: Grant
    Filed: February 7, 2007
    Date of Patent: March 17, 2009
    Assignee: Hoffman-La Roche Inc.
    Inventors: John Frederick Boylan, Jianping Cai, Nader Fotouhi, Paul Gillespie, Robert Alan Goodnow, Jr., Kang Le, Christophe Michoud
  • Thiazolyl-benzimidazoles
    Publication number: 20070203210
    Abstract: The invention is directed to compounds of formula (1) and pharmaceutically acceptable salts thereof, methods for the preparation thereof, and methods of use thereof.
    Type: Application
    Filed: February 7, 2007
    Publication date: August 30, 2007
    Inventors: John Frederick Boylan, Jianping Cai, Nader Fotouhi, Paul Gillespie, Robert Alan Goodnow, Kang Le, Christophe Michoud
  • Thiazoles as inhibitors of 11B-hydroxysteroid dehydrogenase
    Publication number: 20070167622
    Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, type II diabetes mellitus and metabolic syndrome.
    Type: Application
    Filed: January 8, 2007
    Publication date: July 19, 2007
    Inventors: Paul Gillespie, Robert Alan Goodnow, Agnieszka Kowalczyk, Kang Le, Qiang Zhang
  • Hydantoin-containing glucokinase activators
    Patent number: 6784298
    Abstract: Hydantoin compounds which are active as glucokinase activators to increase insulin secretion which makes them useful for treating type II diabetes.
    Type: Grant
    Filed: June 4, 2003
    Date of Patent: August 31, 2004
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Robert Alan Goodnow, Jr., Kang Le
  • Hydantoin-containing glucokinase activators
    Publication number: 20030225286
    Abstract: Hydantoin compounds which are active as glucokinase activators to increase insulin secretion which makes them useful for treating type II diabetes.
    Type: Application
    Filed: June 4, 2003
    Publication date: December 4, 2003
    Inventors: Robert Alan Goodnow, Kang Le
  • Hydantoin-containing glucokinase activators
    Patent number: 6583288
    Abstract: Hydantoin compounds which are active as glucokinase activators to increase insulin secretion which makes them useful for treating type II diabetes.
    Type: Grant
    Filed: April 26, 2001
    Date of Patent: June 24, 2003
    Assignee: Hoffman-La Roche Inc.
    Inventors: Robert Alan Goodnow, Jr., Kang Le
  • Hydantoin-containing glucokinase activators
    Publication number: 20010056191
    Abstract: Hydantoin compounds which are active as glucokinase activators to increase insulin secretion which makes them useful for treating type II diabetes.
    Type: Application
    Filed: April 26, 2001
    Publication date: December 27, 2001
    Inventors: Robert A. Goodnow, Kang Le